Jetema Signs ₩40.2B Exclusive Supply Contract for Botox and Fillers
High impactPredicted impact: High· Actual: −9.7% vs sector, volume 0.6× normal (5 trading days)
Supply contract worth about 52% of last year's revenue, far above the 10% threshold.
Jetema제테마
216080 · KOSDAQ · ₩216080 · 제테마
₩5,960▼ ₩70 (1.16%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −4.33%
- Market cap
- ₩222B
- Enterprise value
- ₩307B
- P/E
- —
- P/B
- 2.7×
- Dividend yield
- 0.0%
- ROE
- −1.6%
- Net margin
- −1.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−47.2% from the high
₩3,800Today: ₩5,910 – ₩6,180₩11,280
Returns
- 1W+0.8%
- 1M−15.2%
- 3M+44.0%
- 6M−15.0%
- YTD−2.6%
- 1Y−4.3%
- Volume today
- 80,117
- 0.6× the 20-day average
- Traded today
- ₩479M
- Listed shares
- 37,287,099
- EPS (12 months)
- −₩36
- Earnings yield −0.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
- MomentumWeak-17.1% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Jetema stock overview
Jetema (제테마, KRX: 216080) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩5,960 on Oct 28, 2026, down 1.16% on the day, giving it a market value of ₩222B.
Key facts
- Market cap
- ₩222B
- Sector
- Biotech & Pharma
- Latest price change
- −1.16%
- As of
- Oct 28, 2026
- Main business
- , Ltd.
Quick answers about Jetema
- What does Jetema do?
- , Ltd. researches, develops and manufactures biopharmaceuticals based on botulinum toxin and hyaluronic acid fillers for facial aesthetic use, along with PDO threads for facial lifting. Its botulinum toxin product Jetema The Toxin was launched in Korea in March 2025 for glabellar lines, and it has licensing and supply deals with partners in Brazil, China and Thailand.
- What is the market cap of Jetema?
- The market capitalisation of Jetema was ₩222B at the close on Oct 28, 2026.
- Who are the largest shareholders of Jetema?
- According to the latest official filings, the largest reported holders are Kim Jae-young (28.94%, as of Oct 29, 2026); Nam Jeong-seon (1.66%, as of Sep 30, 2026); Kim Hyung-seok (0.90%, as of Sep 1, 2026).
- When is the next earnings report from Jetema?
- Korean companies rarely announce results dates in advance. Based on when Jetema filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Jetema?
- Yes. The National Pension Service held 0.01% of Jetema shares as of Dec 31, 2024.
Company profile
Jetema Co., Ltd. researches, develops and manufactures biopharmaceuticals based on botulinum toxin and hyaluronic acid fillers for facial aesthetic use, along with PDO threads for facial lifting. Its botulinum toxin product Jetema The Toxin was launched in Korea in March 2025 for glabellar lines, and it has licensing and supply deals with partners in Brazil, China and Thailand. The company is expanding toward therapeutic markets and the United States, where it has a subsidiary, Jetema USA Inc.
Written by AI from the company's latest annual report.
- Korean name
- 제테마
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 남정선
- Founded
- Jul 2009
- Listed
- Nov 2019
- Listed shares
- 37,287,099
- Fiscal year ends
- Month 12
- Website
- www.jetema.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
JETEMA Begins Botulinum Toxin Export to Thailand
Predicted impact: Low· Actual: −0.8% vs sector, volume 0.6× normal (5 trading days)
Export start to Thailand with no value or revenue share disclosed; small and vague.
Recent filings
See all- 5%+ holding reportOct 29, 2026
- 5%+ holding reportOct 21, 2026
- Major sales or supply contractOct 15, 2026
- Major sales or supply contractOct 15, 2026
- 5%+ holding reportOct 12, 2026
Titles in Korean until English translations are added.
Also known as: Jetema / 제테마 / 216080 / KRX:216080
Source: KRX statistical information